Impact of Airways Function After HFNC Evaluated by IOS

Fu Jen Catholic University Hospital

Status: Completed

Conditions: Small Airway Disorders; COPD

Treatments: Device: high flow nasal cannula and nasal cannula

Study type: Interventional

Funder types: Other

Identifiers

NCT05130112

C107177

Details and patient eligibility

About

In addition to pharmacological treatment, nonpharmacological treatment with high-flow nasal cannula (HFNC) may play a vital role in the treatment of patients with chronic obstructive pulmonary disease (COPD). The impulse oscillation system (IOS) is new noninvasive technique to measure the impedance of different portions of the airway with higher sensitivity than that of the conventional pulmonary function test (PFT). However, whether IOS is an appropriate technique to evaluate the efficacy of HFNC in improving the impedance of peripheral small airways in patients with COPD is unclear.

Full description

Participants with stable COPD from the chest medicine outpatient department will be randomized into two groups receiving HFNC or nasal cannula (NC) for 10 min followed by a 4-week washout period and crossover alternatively. We used a novel analytical measurement technique, IOS, to detect the difference in airway impedance in the participants after the HFNC or NC interventions. All data, namely IOS parameters, transcutaneous partial pressure of carbon dioxide, peripheral oxygen saturation, body temperature, respiratory rate, pulse rate, blood pressure, and PFT results at the time of pre-HFNC, post-HFNC, pre-NC, and post-NC, were analysed using SPSS (version 25.0, IBM, Armonk, NY, USA).

Enrollment: 26 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age of 20 to 75 years old
• diagnosis of COPD made by pulmonologist (Kuo YL) if the patient had a long-term smoking or noxious gas exposure history, typical clinical manifestations, and airflow limitation with a postbronchodilator FEV1/FVC ratio of < 0.7 in spirometry,4 and
• provision of written informed consent.

Exclusion criteria

• severe and unstable comorbidities or active malignancy
• history of obstructive sleep apnoea syndrome
• COPD exacerbation within the 4 weeks prior
• current use of long-term oxygen therapy or noninvasive ventilation or use within the 6 weeks prior
• cognitive impairment or a psychiatric disorder
• pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

26 participants in 2 patient groups

HFNC then NC

Experimental group

Description:

High flow nasal cannula for 10 min (Period 1) and nasal cannula for 10 min (Period 2) after a 4-week washout period

Treatment:

Device: high flow nasal cannula and nasal cannula

NC then HFNC

Experimental group

Description:

Nasal cannula for 10 min (Period 1) and high flow nasal cannula for 10 min (Period 2) after a 4-week washout period

Treatment:

Device: high flow nasal cannula and nasal cannula